<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="871">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00216398</nctid>
  <trial_identification>
    <studytitle>Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR</studytitle>
    <scientifictitle>A Phase IV, Multicentre, Open-Label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A-9B-52030-159</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acromegaly</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lanreotide (Autogel formulation)

Treatment: drugs: Lanreotide (Autogel formulation)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The percentage of patients with GH control (&lt;5.0 mU.L) and normalised IGF-1 at week 44 compared to the baseline (Week 0) visit.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of patients with GH control (&lt; 5.0 mU/L) at each visit to week 44 compared to the baseline (Week 0) visit.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of patients with normalised IGF-1 compared to the baseline visit.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in the GH values compared to the baseline (Week 0) visit.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in the IGF-1 values compared to the baseline (Week 0) visit.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in serum lanreotide levels compared to the baseline (Week 0) visit.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in the serum octreotide levels compared to the baseline visit.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient evaluation of lanreotide Autogel treatment compared with evaluation of octreotide LAR treatment.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Investigator evaluation of lanreotide Autogel treatment compared with evaluation of octreotide LAR treatment.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Clinical diagnosis of acromegaly

          -  The patient must have been tested at Week -4 (4 weeks prior to the Baseline visit) and
             shown to have a GH level &lt;10 mU/L.

          -  The patient must have been treated with a stable dose of octreotide LAR for at least
             four months prior to study entry

          -  Life expectancy of at least 2 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Adenectomy within past 6 months, or likely during study period

          -  Radiotherapy for acromegalic disease within 1 year, or likely during study period

          -  Unstable concomitant dopamine agonist therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Westmead Hospital - Westmead</hospital>
    <postcode>2145 - Westmead</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ipsen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the efficacy, safety and patient acceptability of
      Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00216398</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hugues Berard, MD</name>
      <address>Ipsen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>